VRTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VRTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Vertex Pharmaceuticals's share price for the quarter that ended in Sep. 2024 was $465.08. Vertex Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 258 Mil. Therefore, Vertex Pharmaceuticals's market cap for the quarter that ended in Sep. 2024 was $119,870 Mil.
Vertex Pharmaceuticals's quarterly market cap increased from Mar. 2024 ($107,970 Mil) to Jun. 2024 ($120,937 Mil) but then declined from Jun. 2024 ($120,937 Mil) to Sep. 2024 ($119,870 Mil).
Vertex Pharmaceuticals's annual market cap increased from Dec. 2021 ($55,884 Mil) to Dec. 2022 ($74,220 Mil) and increased from Dec. 2022 ($74,220 Mil) to Dec. 2023 ($104,854 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Vertex Pharmaceuticals's Enterprise Value for Today is $116,016 Mil.
The historical data trend for Vertex Pharmaceuticals's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Market Cap | Get a 7-Day Free Trial | 56,706.52 | 61,422.40 | 55,883.59 | 74,219.93 | 104,853.52 |
Vertex Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Market Cap | Get a 7-Day Free Trial | 89,657.46 | 104,853.52 | 107,970.31 | 120,936.79 | 119,869.72 |
For the Biotechnology subindustry, Vertex Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Vertex Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
Market Cap (A: Dec. 2023 ) | = | Share Price (A: Dec. 2023 ) | * | Shares Outstanding (EOP) (A: Dec. 2023 ) |
= | $406.89 | * | 257.695 | |
= | $104,854 |
Vertex Pharmaceuticals's Market Cap for the quarter that ended in Sep. 2024 is calculated as
Market Cap (Q: Sep. 2024 ) | = | Share Price (Q: Sep. 2024 ) | * | Shares Outstanding (EOP) (Q: Sep. 2024 ) |
= | $465.08 | * | 257.74 | |
= | $119,870 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals (NAS:VRTX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
David Altshuler | officer: EVP, Global Research and CSO | C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139 |
Wagner Charles F Jr | officer: EVP & Chief Financial Officer | C/O MILLIPORE CORP, BILLERICA MA 01820 |
Reshma Kewalramani | director, officer: CEO & President | C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210 |
Jonathan Biller | officer: EVP and Chief Legal Officer | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Jeffrey M Leiden | director | 15 N BEACH ROAD, HOBE SOUND FL 33455 |
Sangeeta N. Bhatia | director | C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210 |
Carmen Bozic | officer: EVP and CMO | C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210 |
Bruce I Sachs | director | C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210 |
Atkinson Edward Morrow Iii | officer: EVP, Chief Technical Ops. Off. | C/O 89BIO, INC., 142 SANSOME STREET, SECOND FLOOR, SAN FRANCISCO CA 94104 |
Ourania Tatsis | officer: EVP, Chief Reg. & Quality Off. | C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210 |
Kristen Ambrose | officer: SVP & Chief Accounting Officer | C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON MA 02210 |
Stuart A Arbuckle | officer: EVP, COO | VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST., CAMBRIDGE MA 02139 |
Amit Sachdev | officer: SVP, Public Policy,Gov Affairs | C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139 |
Michel Lagarde | director | 450 LEXINGTON AVE., 31ST FLOOR, NEW YORK NY 10017 |
Terrence C Kearney | director | IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045 |
From GuruFocus
By Business Wire • 11-04-2024
By GuruFocus News • 11-05-2024
By Business Wire • 09-26-2024
By GuruFocus News • 11-05-2024
By Business Wire • 08-08-2024
By GuruFocus News • 11-13-2024
By Business Wire • 10-25-2024
By GuruFocus Research • 07-12-2024
By GuruFocus Research • 07-24-2024
By Business Wire • 10-10-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.